Proceedings from a CME symposium held at the 2012 ASCO Annual Meeting. Featuring perspectives from Drs Harold J Burstein, Angelo Di Leo, Ana Maria Gonzalez-Angulo, Mark D Pegram and Hope S Rugo. (Video Program)
TARGET AUDIENCE
This activity is intended for medical oncologists, breast surgeons and other healthcare providers involved in the treatment of breast cancer.
OVERVIEW OF ACTIVITY
Breast cancer remains the most frequently diagnosed cancer in women, and it is estimated that 226,870 new cases and approximately 40,000 attributable deaths will occur in the United States in 2012 alone. Advances in screening and prevention have resulted in a steady down-stage migration at the time of disease presentation, such that only 5% of women have identifiable distant metastases at primary diagnosis. Consequently, the number of individuals living with breast cancer has increased substantially, as has the population “at risk” for recurrent disease.
The current clinical management of breast cancer is multidisciplinary and includes surgical resection of local disease with or without radiation therapy and the treatment of systemic disease (micro- or macroscopic) with cytotoxic chemotherapy, endocrine therapy, biologic therapy or combinations of these agents. In addition, diagnosis may now include description of a molecular subtype, derived from either gene microarray analysis or simply immunohistochemical cellular receptor expression profiles. By providing access to the latest research developments and expert perspectives, these proceedings from a case-based CME symposium held at the 2012 ASCO Annual Meeting aims to assist medical oncologists, breast surgeons and other healthcare providers as they attempt to formulate optimal disease management strategies in the face of a constantly evolving body of knowledge.
LEARNING OBJECTIVES
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME credit is no longer available for this issue
CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue
HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. The participant should watch the video.
CME credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
Harold J Burstein, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts
No real or apparent conflicts of interest to disclose.
Angelo Di Leo, MD, PhD
Head of Sandro Pitigliani Medical Oncology Unit
Department of Oncology
Hospital of Prato
Istituto Toscano Tumori
Prato, Italy
Advisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Genomic Health Inc, Roche Laboratories Inc, Sanofi.
Ana Maria Gonzalez-Angulo, MD, MSc
Associate Professor
Department of Breast Medical Oncology
Department of Systems Biology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Advisory Committee: Bayer HealthCare Pharmaceuticals; Paid Research: Bristol-Myers Squibb Company, Celgene Corporation, Novartis Pharmaceuticals Corporation; PI on Trial: Genomic Health Inc.
Mark D Pegram, MD
Director, Breast Oncology Program
Co-Director, Experimental Therapeutics Program
Professor of Medicine
Stanford University Medical Center
Stanford, California
Advisory Committee: Amgen Inc, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Millennium: The Takeda Oncology Company; Consulting Agreement: Genentech BioOncology; Data and Safety Monitoring Board: Pfizer Inc.
Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Paid Research: Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi.
MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Pharmaceuticals.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Eisai Inc, Genentech BioOncology and Genomic Health Inc.
Hardware/Software Requirements:
An Internet connection that is at least 28.8 Kbps
A monitor set to 1280 x 1024 pixels or more
Netscape 7.x or newer, Internet Explorer 5.x or newer, or Firefox
Macromedia Flash plug-in 6.0 or greater
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: July 2012
Expiration date: July 2013
Introduction: Dr Love | |
Module 1 – Dr Burstein: Metastatic HER2-Positive Breast Cancer |
|
Module 2 – Dr Gonzalez-Angulo Adjuvant Chemo and Genomic Assays |
|
Module 3 – Dr Rugo: Metastatic HER2-Negative Breast Cancer |
|
Module 4 – Dr Pegram: HER2-Positive Early Breast Cancer |
|
Module 5 – Dr Di Leo: Metastatic ER-Positive Breast Cancer |
Watch video
(WiFi is recommended for best performance):